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This is one of the few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in
predicting survival in brain cancer patients. Baseline HRQOL scores (from the EORTC QLQ-C30 and the Brain Cancer Module (BN
20)) were examined in 490 newly diagnosed glioblastoma cancer patients for the relationship with overall survival by using Cox
proportional hazards regression models. Refined techniques as the bootstrap re-sampling procedure and the computation of
C-indexes and R
2-coefficients were used to try and validate the model. Classical analysis controlled for major clinical prognostic
factors selected cognitive functioning (P¼0.0001), global health status (P¼0.0055) and social functioning (Po0.0001) as statistically
significant prognostic factors of survival. However, several issues question the validity of these findings. C-indexes and R
2-coefficients,
which are measures of the predictive ability of the models, did not exhibit major improvements when adding selected or all HRQOL
scores to clinical factors. While classical techniques lead to positive results, more refined analyses suggest that baseline HRQOL
scores add relatively little to clinical factors to predict survival. These results may have implications for future use of HRQOL as a
prognostic factor in cancer patients.
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It has become increasingly accepted that, in addition to the
traditional assessment of clinical outcomes, health-related quality-
of-life (HRQOL) information can play a key role in cancer research
and may help in individual patient care (Detmar et al, 2002;
Velikova et al, 2004). Patients’ self-assessment of HRQOL is now
an established end point for treatment comparisons in many
cancer disease sites (Bottomley et al, 2003), particularly in
advanced disease (Efficace et al, 2004a; Bottomley et al, 2005).
Theoretically, HRQOL outcomes could have various clinical
applications, including supporting clinical decision-making by
providing the patient’s perspective or providing prognostic
information. Recent studies have shown that HRQOL parameters
can be independent prognostic factors for survival in cancer
patients (Kramer et al, 2000). If HRQOL parameters are
independent predictors of survival, they could be used in daily
practice to identify patients who will benefit from a specific
intervention; further, it could help to avoid over-treatment of
patients who will gain no benefit from, often, toxic and aggressive
therapies or to set up more tailored psychosocial intervention
programmes aimed at improving patients’ HRQOL. Furthermore,
they could be used to better stratify patients in future cancer
clinical trials, hence better interpreting study outcomes or helping
identify critical areas that could help in the selection of key end
points for future clinical trials.
Health-related quality-of-life prognostic factor analyses have
been carried out on several different cancer populations, including,
among others, lung (Herndon et al, 1999; Langendijk et al, 2000;
Montazeri et al, 2001; Efficace et al, 2006), oesophageal (Blazeby
et al, 2001; Fang et al, 2004), advanced breast (Luoma et al, 2003;
Efficace et al, 2004a), and head and neck (de Graeff et al, 2001)
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scancers, highlighting the importance HRQOL scores may have in
predicting survival. Only three studies have examined HRQOL
and/or cognitive functioning as a prognostic factor in brain cancer
(Meyers et al, 2000; Klein et al, 2003; Sehlen et al, 2003). The
present study evaluates the prognostic value of HRQOL data
collected from a prospective, large-scale international randomised
controlled trial, by using various statistical techniques in an
attempt to provide robust conclusions on the prognostic value of
HRQOL in glioblastoma multiforme patients.
METHODS
Treatment
In this international, multicentre study (EORTC trial 26981-22981-
NCIC CE3), 573 patients with newly diagnosed glioblastoma were
randomised to treatment with radiotherapy (RT) only or RT with
concomitant temozolomide (TMZ) chemotherapy followed by six
cycles of TMZ chemotherapy. Patients were stratified for institu-
tion, performance status (WHO performance status 0 or 1 vs 2),
age (o50 vs X50 years) and the extent of the resection at surgery
(biopsy only vs debulking surgery/resection). The details on trial
conduct and clinical outcome have previously been reported (Hegi
et al, 2005; Stupp et al, 2005; Mirimanoff et al, 2006). The trial was
approved by the EORTC protocol review committee and the ethics
committee of each participating centre. All patients provided
written informed consent.
Procedures
Health-related quality-of-life evaluations The primary end point
of the clinical trial was survival, with HRQOL being a secondary
end point. Two HRQOL measures were selected for the trial: the
EORTC Quality of Life Questionnaire C30 (EORTC QLQ-C30,
version 2) (Aaronson et al, 1993) and the EORTC QLQ-Brain
Cancer Module (QLQ-BN20) (Osoba et al, 1996). Both tools have
robust psychometric properties resulting from rigorous testing and
development from their use in several international cancer clinical
trials (Bottomley et al, 2003). The EORTC QLQ-C30 is a core
measure designed to be supplemented with disease-specific
questionnaires. The EORTC QLQ-BN20 was developed specifically
in patients with brain cancer. Both instruments were available in
the language of all participating patients (Cull et al, 2002).
The EORTC QLQ-C30 measure comprises five functioning scales
– physical, role, emotional, cognitive and social; three symptom
scales – fatigue, nausea/vomiting and pain; six single item scales –
dyspnoea, insomnia, appetite loss, constipation, diarrhoea and
financial impact; and the overall health/global QOL scale.
The EORTC QLQ-BN20, designed for use with patients under-
going chemotherapy or RT, includes 20 items assessing visual
disorders, motor dysfunction, communication deficit, various
disease symptoms (e.g. headaches and seizures), treatment
toxicities (e.g. hair loss) and future uncertainty.
The items on both measures were scaled and scored using the
recommended EORTC procedures (Fayers et al, 2001). Raw scores
were transformed to a linear scale ranging from 0 to 100, with a
higher score representing a higher level of functioning or higher
level of symptoms. Provided at least half of the items in the scale
were completed, the scale score was calculated using only those
items for which values existed.
Patients were randomised following surgery and before the start
of the RT. Radiotherapy started within 6 weeks after surgery. Valid
HRQOL assessments were performed at baseline, before the start
of therapy, not more than 1 month before randomisation and not
more than 2 weeks after randomisation.
Health-related quality of life was a mandatory aspect of this
clinical trial protocol. The protocol stipulated that a responsible
nurse, clinician or data manager administered the questionnaire,
requesting completion and its return to the EORTC Data Centre.
The EORTC guidelines for administering questionnaires were
provided, ensuring a standard approach and optimal compliance
of HRQOL data collection by all personnel.
Statistical analysis
For this analysis, only baseline HRQOL scores were used. To
minimise the risk of false-positive results, we excluded a priori
several HRQOL scales (seven from the QLQ-C30 and two from the
brain module) from the analyses. The variables selected to be
excluded were not expected to have any prognostic value or
alternatively were known to be highly inter-correlated with other
scales, thereby not contributing to the model. The final analysis
included 17 HRQOL variables: eight (appetite loss, cognitive
functioning, emotional functioning, fatigue, physical functioning,
global health status, social functioning, insomnia) from the core
questionnaire and nine (bladder control, communication deficit,
drowsiness, future uncertainty, headaches, motor dysfunction,
seizures, visual disorder, weakness of legs) from the brain module.
The Cox proportional hazards regression model (Cox, 1972)
with overall survival measured from the time of randomisation as
dependent outcome was used for both univariate and multivariate
analyses. A Collett’s Model Selection approach (Collett, 1994) was
used with a level of significance of 0.15 for the univariate screening
and stay and entry criterion of 0.05. The HRQOL scales were
included as continuous factors. The model was controlled for the
major established prognostic baseline clinical factors (Gorlia et al,
in press): age (o50 vs X50 years), performance status (0 vs 1 vs 2),
extent of surgery (complete resection vs partial resection vs biopsy
only), corticosteroids at entry (yes vs no), mini-mental state
examination (o27 vs 27–30), O
6-methylguanine-DNA methyl-
transferase (MGMT) promoter methylation status (yes vs no) as
well as randomly assigned therapy. The MGMT status could only
be assessed in 36% of the patients and was shown to be predictive
of a favourable treatment effect in patients receiving TMZ
chemotherapy (Hegi et al, 2005). The MGMT promoter methyla-
tion status was included in the analysis as a stratum with three
levels (methylated, unmethylated or missing). The treatment
assignment was also included as a stratum (because of the
interaction between treatment and MGMT methylation). All other
factors were included as covariates.
Validation of the final model was undertaken by use of several
refined statistical techniques. The stability of the final model was
investigated using a bootstrap re-sampling procedure as proposed
by Sauerbrei and Schumacher (1992), applied in the context of
HRQOL (Van Steen et al, 2002). This technique generates a
number of samples (each of the same size as the original data set),
by randomly selecting patients and replacing them before selecting
the next patient (i.e. bootstrap resampling). The frequency of
inclusion of the HRQOL scores in the Cox PH regression models,
including all the selected clinical factors and treatment, fitted to
each of these data sets using automatic forward stepwise selection
(entry level of a¼0.05), can be considered to be indicative for the
importance of the HRQOL factors. This technique was applied to
1000 bootstrap samples.
Deviance residuals from the model with clinical factors were
plotted vs the HRQOL scores to explore the relationship between
each HRQOL score and the remaining part of the hazard not
already explained by clinical factors. Finally, discrimination
C-indexes and Nagelkerke’s R
2 coefficients were computed to
quantify the predictive accuracy of a model. C-index is a measure
of how well a model is able to rightly predict which patient among
a randomly chosen pair of patients will survive longer.
Nagelkerke’s R
2-coefficient is a generalisation of the R
2-coefficient
in linear regression, which measures the percentage of variation in
the dependent variable accounted for by the predictor variables. It
Prognostic value of baseline HRQOL in glioblastoma
M Mauer et al
303
British Journal of Cancer (2007) 97(3), 302–307 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
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responses based on the predictor variables.
All data analyses were performed using Statistical Analysis
Software (SAS) version 9.
RESULTS
Between June 2000 and March 2002, 573 patients from 85
institutions in 15 countries were randomised to receive either RT
alone (286 patients) or RT with TMZ (287 patients). Of these
patients, 248 (RT) and 242 (RT plus TMZ) had baseline HRQOL
measures completed. In total, 83 (RT) and 86 (RT plus TMZ) had
an assessment of their methylation status of the MGMT promoter.
The analysis was performed on 490 patients with baseline HRQOL
measures that represent 85.5% of the original sample size.
Clinical and quality-of-life results
The clinical results have been published (Hegi et al, 2005; Stupp
et al, 2005; Mirimanoff et al, 2006). In brief, the study
demonstrated that the addition of TMZ to RT for newly diagnosed
glioblastoma resulted in a clinically meaningful and statistically
significant survival benefit with minimal additional toxicity
(unadjusted hazard ratio of 0.63 with a 95% confidence interval,
0.52–0.75; Po0.001 by the log-rank test). In addition, patients
whose tumours had a methylated MGMT gene promoter benefited
from TMZ, whereas those who did not have a methylated MGMT
promoter derived no or only limited benefit from the addition of
chemotherapy. Quality-of-life results have also been published
(Taphoorn et al, 2005). Addition of TMZ during and after RT
significantly improved survival without a negative effect on
HRQOL. Baseline clinical characteristics for patients with a valid
baseline HRQOL questionnaire are depicted in Table 1.
The distribution of the baseline clinical characteristics was very
similar between patients with a valid baseline HRQOL question-
naire and those without. When comparing patients with and those
without available MGMT assessment, imbalances were noticed for
the clinical characteristics age, MMSE score, extent of surgery and
tumour location. The percentages of patients under 50 years, with
an MMSE above 27 or with a unifocal tumour location are higher
in patients with a MGMT status. The subgroup of patients with
MGMT promoter methylation status assessed was therefore not
entirely representative of the whole trial population. A higher
proportion of patients with resected tumours had the MGMT
status successfully assessed due to the lack of a sufficient amount
of tumour tissue in stereotactic biopsies.
Prognostic factor analysis results
Univariate analysis When controlled for the major prognostic
clinical factors, the HRQOL scores that passed the 15% significance
level were cognitive functioning, fatigue, global health status, social
functioning, bladder control, headaches and motor dysfunction.
Table 2 shows the results of this analysis.
Multivariate analysis
The Cox multivariate model selected by Collett’s Model Selection
approach contained cognitive functioning, global health status and
social functioning in addition to the selected clinical factors
(Table 3). However, the sign of the coefficient related to social
functioning was opposite to what was expected, that is, worse
social functioning was related to better survival.
Bootstrap re-sampling procedure
Table 4 presents the results of the bootstrap re-sampling
procedure. The inclusion frequencies above 50% were related to
cognitive functioning (83.0%), global health status (55.2%) and
social functioning (88.9%). The frequencies of selection of each
possible set of HRQOL scores were very low. The most frequently
selected model (cognitive functioning, global health status, social
functioning) was selected only 8.8% of the time. This indicates a
high degree of model instability with no single model to be
uniformly preferable over all others.
Discrimination index C and Nagelkerke’s R
2 coefficient
Discrimination C-indexes and Nagelkerke’s R
2 coefficients were
computed for the model with clinical prognostic factors only and
for various models with added HRQOL scores. The C-index of the
model with only clinical baseline characteristics is C¼0.647 and
the Nagelkerke’s R
2-coefficient is R
2¼0.133. When adding HRQOL
scores, C¼0.654 and R
2¼0.177 for the three selected HRQOL
scores and C¼0.647 and R
2¼0.189 for all HRQOL scores. For the
model without clinical factors but with all HRQOL scores,
C¼0.604 and R
2¼0.104.
DISCUSSION
Glioblastoma, like any other malignant brain tumour, have
a considerable impact on the patient’s HRQOL, and in spite of
Table 1 Baseline clinical characteristics of patients with HRQOL
Baseline characteristics
Treatment
RT
(N¼248)
RT+TMZ
(N¼242)
Total
(N¼490)
N (%) N (%) N (%)
Age (years)
o50 72 (29.0) 75 (31.0) 147 (30.0)
X50 176 (71.0) 167 (69.0) 343 (70.0)
Sex
Male 152 (61.3) 153 (63.2) 305 (62.2)
Female 96 (38.7) 89 (36.8) 185 (37.8)
MMSE score
o27 78 (31.5) 68 (28.1) 146 (29.8)
27–30 167 (67.3) 168 (69.4) 335 (68.4)
Missing 3 (1.2) 6 (2.5) 9 ( 1.8)
PFS (WHO)
0 95 (38.3) 96 (39.7) 191 (39.0)
1 120 (48.4) 113 (46.7) 233 (47.6)
2 33 (13.3) 33 (13.6) 66 (13.5)
Corticosteroids at entry
No 63 (25.4) 78 (32.2) 141 (28.8)
Yes 185 (74.6) 164 (67.8) 349 (71.2)
Extent of surgery
Biopsy only 39 (15.7) 38 (15.7) 77 (15.7)
Partial resection 116 (46.8) 107 (44.2) 223 (45.5)
Total resection 93 (37.5) 97 (40.1) 190 (38.8)
Tumour location
Unifocal 206 (83.1) 198 (81.8) 404 (82.4)
Multifocal+other 42 (16.9) 44 (18.2) 86 (17.6)
MGMT
Methylated 38 (15.3) 40 (16.5) 78 (15.9)
Unmethylated 48 (19.4) 49 (20.2) 97 (19.8)
Missing 162 (65.3) 153 (63.2) 315 (64.3)
Prognostic value of baseline HRQOL in glioblastoma
M Mauer et al
304
British Journal of Cancer (2007) 97(3), 302–307 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
simportant progress due to the addition of chemotherapy to RT and
surgery, as a rule most glioblastoma patients will eventually suffer
from tumour relapse. With such a poor prognosis, evaluation of
patients’ HRQOL before and during treatments becomes impor-
tant. In this study, we explored if HRQOL data provide reliable and
useful prognostic information. Our study used 490 glioblastoma
patients, controlled for major prognostic clinical factors, and
attempted to overcome limitations of past studies by using a larger
sample size of homogeneously treated patients and sophisticated
statistical methodology.
Previous studies in brain tumour patients showed that HRQOL
factors and/or cognitive functioning were statistically significant
factors in prediction models for groups of patients, comparable to
our classical analysis. For example, Sehlen et al (2003) examined
HRQOL in 153 patients with either malignant astrocytoma or brain
metastases. Using the Functional Assessment of Cancer Therapy
General HRQOL measure (Cella et al, 1993), they found two
variables, that is, ‘living with a spouse’ and the FACT-G total score
to predict survival. Two other studies demonstrated objective
cognitive functioning to have prognostic significance, both in
newly diagnosed and in recurrent high-grade glioma (Meyers et al,
2000; Klein et al, 2003). Meyers et al (2000) examined HRQOL and
cognitive functioning in 80 patients with recurrent malignant
glioma or anaplastic astrocytoma, at baseline, before treatment in
phase I and II trials. Health-related quality of life was undertaken
with the FACT-BR module, along with other neuropsychological
tests. Health-related quality-of-life scores did not predict survival,
but cognitive functioning was a significant predictor of survival. It
is difficult to compare these findings with our results, given the
different measures that were used, along with their sample being
relatively small. In addition, the Phase I/II setting of Meyers et al is
likely to be considerably different (higher expectations and
discounting toxicities) to that of a large phase III trial (Cheng
et al, 2000). Klein et al (2003) explored cognitive functioning along
with activities of daily living in 68 newly diagnosed high-grade
glioma patients. Cognitive functioning had prognostic value, but
only in a subsample of older patients. However, it is unclear to
what extent studies on such small samples can be relied on for
providing definitive conclusions. It is also difficult to make
comparisons between our trial and Klein et al. due to the different
HRQOL measures employed.
There are several issues questioning the validity and the
reliability of the results obtained by classical techniques. Some of
them are well known, such as the large number of HRQOL scales
and the intercorrelation of these HRQOL scales. It makes the
selection of a particular set of HRQOL scores quite difficult as
various sets of HRQOL scores may predict equally survival when
added to clinical factors. It may also lead to models difficult to
interpret (with worst HRQOL status associated with longer
survival) as some HRQOL factors may enter the model just as
corrections for others. In addition, as HRQOL scores are analysed
as continuous factors, the results could be influenced by a few
‘outliers’, that is, patients with some very bad HRQOL scores but
who actually survived long or vice versa. Furthermore, the
residuals plots also suggested a high variability in duration of
survival among patients who have a same level of the HRQOL
scores.
Table 2 Univariate prognostic factor analyses for survival (controlled for
clinical factors)
HRQOL scores
a Hazard ratio (HR)
95% confidence
interval (CI) P-value
EORTC QLQ-C30
Appetite loss 1.017 0.967 1.069 0.5088
Cognitive functioning 0.919 0.887 0.953 o0.0001
Emotional functioning 0.983 0.943 1.025 0.4162
Fatigue 1.063 1.022 1.106 0.0025
Physical functioning 0.927 0.890 0.967 0.0004
Global health status 0.939 0.901 0.977 0.0022
Social functioning 1.012 0.981 1.044 0.4504
Insomnia 0.994 0.961 1.029 0.7308
EORTC QLQ-BN20
Bladder control 1.066 1.019 1.115 0.0055
Communication deficit 1.088 1.046 1.132 o0.0001
Drowsiness 1.021 0.982 1.061 0.2967
Future uncertainty 1.019 0.983 1.055 0.3051
Headaches 1.024 0.984 1.065 0.2373
Motor dysfunction 1.092 1.048 1.139 o0.0001
Seizures 1.079 1.020 1.140 0.0079
Visual disorder 1.028 0.966 1.093 0.3857
Weakness of legs 1.044 1.005 1.084 0.0276
aFor every 10 point shift in the scale ranging between 0 and 100.
Table 4 Inclusion frequencies in the bootstrap re-sampling procedure
Variable
Inclusion
(%)
Pos. incl.
(%)
Neg. incl.
(%)
Age (o50 vs X50) 100.0 96.9 3.1
Partial resection vs biopsy 100.0 14.0 86.0
Total resection vs biopsy 100.0 1.3 98.7
Performance status (1 vs 0) 100.0 75.9 24.1
Performance status (2 vs 0) 100.0 67.9 32.1
MMSE (o27 vs 27–30) 100.0 0.3 99.7
Corticosteroids at entry (yes vs no) 100.0 99.9 0.1
Appetite loss 8.6 5.9 2.7
Cognitive functioning 83.0 0.0 83.0
Emotional functioning 7.5 6.6 0.9
Fatigue 8.6 7.7 0.9
Physical functioning 6.6 2.8 3.8
Global health status /QoL 55.2 0.0 55.2
Social functioning 88.9 88.9 0.0
Insomnia 20.5 0.1 20.4
Bladder control 24.2 24.2 0.0
Communication deficit 11.9 0.9 11.0
Drowsiness 5.2 2.3 2.9
Future uncertainty 27.4 27.3 0.1
Headaches 8.9 7.9 1.0
Motor dysfunction 20.0 20.0 0.0
Seizures 13.4 13.1 0.3
Visual disorder 9.4 5.8 3.6
Weakness legs 20.6 1.0 19.6
Positive inclusion is any inclusion of the factor in a model with a positive coefficient.
Negative inclusion is any inclusion of the factor in a model with a negative coefficient.
Table 3 Multivariate model predicting survival for patients with HRQOL
Variables Hazard ratio (HR)
95%
confidence
interval
(CI) P-value
Clinical variables
Age (o50 vs X50 years) 1.274 1.008 1.611 0.0430
Biopsy vs partial resection 0.830 0.614 1.121 0.2246
Biopsy vs total resection 0.618 0.448 0.853 0.0034
Performance status (0 vs 1) 1.069 0.844 1.354 0.5803
Performance status (0 vs 2) 1.170 0.825 1.659 0.3780
MMSE (o27 vs 27–30) 0.679 0.536 0.861 0.0014
Corticosteroids at entry (no vs yes) 1.583 1.242 2.016 0.0002
HRQOL scores
a
Cognitive functioning 0.918 0.878 0.959 0.0001
Global health status 0.929 0.882 0.979 0.0055
Social functioning 1.090 1.046 1.137o0.0001
aFor every 10 point shift in the scale ranging between 0 and 100.
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2-coefficients are thought to better assess the
potential benefit of using baseline HRQOL scores in addition to the
clinical factors to predict survival in clinical practice and research.
In our study, the calculated coefficients did not exhibit major
improvement when adding selected or all HRQOL scores to clinical
factors, suggesting that baseline HRQOL scores in the end add
relatively little to known clinical factors to predict survival and
cannot be used alone in outcome prediction.
Care needs to be taken when interpreting the results of our
study, given our study had limitations, particularly as this was an
exploratory analysis. Also, while 490 patients represent a
considerable sample, other data sets are required to validate these
findings.
In summary, while traditional methods of analysis suggest
HRQOL data are prognostic, more detailed analysis revealed these
findings may not be as reliable as expected. Further research
should investigate the use of HRQOL with more sophisticated
techniques to obtain reliable results.
The investigation of the prognostic value of HRQOL data is a
challenging and ongoing research area. Further research could also
investigate the prognostic value of changes from baseline in
HRQOL rather than baseline values and should investigate why
HRQOL parameters might be of value in one setting but not
another. Furthermore, the reason for this association between
HRQOL data and survival is unclear. Some hypotheses have been
proposed to explain the mechanisms underlying the association.
Patients’ HRQOL scores might reflect an early perception of the
severity of the disease in a more accurate way than conventional
prognostic indices. In this case, patients who report worse HRQOL
scores are the ones with a worse underlying disease. This
hypothesis does not imply a true causative relationship between
HRQOL parameters and survival. On the other hand, it is also
possible that a better HRQOL score (which reflects a better
physical and psychological state) could somehow have a positive
effect on the disease process by, for example, slowing tumour
progression. This causative explanation could be supported by
some intervention studies which have shown that psychosocial
support improved both psychological well-being and survival time.
Coates et al (2000) assumed that, if the mechanism underlying the
association between HRQOL and survival is causative, one should
expect to see HRQOL parameters being prognostic of clinical
outcomes, not only in patients with metastatic disease, but also at
an earlier stage of the disease. Given this assumption, and the fact
that their study did not find a correlation between HRQOL
parameters and disease-free survival in their nonmetastatic breast
cancer population, the authors argued in favour of the explanation
that HRQOL scores reflect a more accurate perception of the
severity of the underlying illness. The results of Efficace et al
(2004a,b) also seem to support this view. Hence, it would be
possible to speculate that for early stage disease, clinical
examinations (such as performance status or tumour staging)
are more likely to supersede patients’ self-reported HRQOL scores
in predicting survival. However, more studies are required to
definitively exclude any possible causative relationship with
survival.
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